Grifols (NASDAQ:GRFS) Upgraded to “Buy” at StockNews.com

StockNews.com upgraded shares of Grifols (NASDAQ:GRFS – Get Rating) from a hold rating to a buy rating in a research note issued to investors on Monday.

A number of other research analysts also recently issued reports on the stock. AlphaValue upgraded shares of Grifols to a buy rating in a research report on Monday, February 6th. Barclays upgraded Grifols from an underweight rating to an equal weight rating in a research report on Thursday, February 16th. Morgan Stanley lowered Grifols from an overweight rating to an equal weight rating in a research report on Friday, March 3rd. Jefferies Financial Group raised Grifols from a hold rating to a buy rating in a research report on Wednesday, January 18th. Finally, Credit Suisse Group initiated coverage on shares of Grifols in a report on Friday, November 25th. They set a neutral rating for the company. Four analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of Moderate Buy and an average target price of $12.52.

Grifols Stock Up 0.1 %

GRFS stock opened at $7.64 on Monday. The stock’s 50 day simple moving average is $9.18 and its 200 day simple moving average is $8.05. The company has a debt-to-equity ratio of 1.18, a current ratio of 2.38 and a quick ratio of 0.74. Grifols has a 12-month low of $5.71 and a 12-month high of $13.34.

Hedge Funds Weigh In On Grifols

A number of institutional investors and hedge funds have recently bought and sold shares of GRFS. Captrust Financial Advisors boosted its holdings in shares of Grifols by 153.5% in the second quarter. Captrust Financial Advisors now owns 2,086 shares of the biotechnology company’s stock valued at $25,000 after acquiring an additional 1,263 shares in the last quarter. Amundi increased its position in shares of Grifols by 2,512.9% during the 4th quarter. Amundi now owns 3,632 shares of the biotechnology company’s stock valued at $33,000 after purchasing an additional 3,493 shares during the period. Ronald Blue Trust Inc. bought a new stake in shares of Grifols in the 4th quarter worth $38,000. Quadrant Capital Group LLC lifted its holdings in shares of Grifols by 54.0% in the fourth quarter. Quadrant Capital Group LLC now owns 4,859 shares of the biotechnology company’s stock valued at $41,000 after buying an additional 1,703 shares during the period. Finally, Brinker Capital Investments LLC bought a new position in Grifols during the third quarter valued at about $69,000. Institutional investors own 14.41% of the company’s stock.

Grifols Company Profile

(Get Rating)

Grifols SA engages in the production of plasma derivatives. It operates through the following segments: Bioscience, Hospital, Diagnostic, Bio Supplies, and Others. The Bioscience Segment includes all activities related with products deriving from human plasma for therapeutic use. The Hospital Segment comprises of all non-biological pharmaceutical products and medical supplies manufactured by group companies earmarked for hospital pharmacy.